Is there a role for hormone replacement therapy after breast cancer?

Journal of the British Menopause Society

Volumn 11, Issue 4, 2005, Pages 140-144

  Kwan, Kenny ^a   Ward, Charlotte ^a   Marsden, Jo ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Breast cancer; Hormone replacement therapy; Menopause; Selective serotonin reuptake inhibitors; Tibolone

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; CITALOPRAM; ESTROGEN; ESTROGEN RECEPTOR; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TIBOLONE; VENLAFAXINE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DRUG SAFETY; EARLY CANCER; ESTROGEN DEFICIENCY; ESTROGEN SYNTHESIS; HORMONE SENSITIVITY; HORMONE SUBSTITUTION; HUMAN; LIFE EXPECTANCY; MENOPAUSE; NOTE; OVULATION INHIBITION; QUALITY OF LIFE; SYSTEMIC THERAPY; UNITED KINGDOM; VAGINAL DRYNESS; VASOMOTOR DISORDER;

BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; QUALITY OF LIFE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SURVIVORS; TAMOXIFEN; WOMEN'S HEALTH;

EID: 30844438489     PISSN: 13621807     EISSN: 13621807     Source Type: Journal    
DOI: 10.1258/136218005775544273     Document Type: Note

References (18)

1. Cancer Research UK. Breast Cancer Factsheet, February 2004. See http://www.cancerresearchuk.org/aboutcancer/statistics/statsmisc/pdfs/ factsheet_breast_feb2004.pdf (last accessed 13 October 2005)
2. Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 1995;13:2737-44
3. Holmberg, L, Anderson H, for the HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped. Lancet 2004;363:453-5
4. von Schoultz; E, Rutqvist LE, on behalf of the Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomised trial. J Natl Cancer Inst 2005;97:533-5
5. Dew JE, Wren BG, Eden JA. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study. Climacteric 2002;5:151-5
6. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
7. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27
8. Marsden J, Sacks NPM, Baum M, A'Hern R, Whitehead MI. Are randomised trials of hormone replacement therapy in symptomatic breast cancer patients feasible? Fert Steril 2000;73:292-9
9. Veronesi U, Maisonneuve P, Sacchini V, the Italian Tamoxifen Study Group. Tamoxifen for breast cancer among hysterectomised women. Lancet 2002;359:1122-3
10. Col NF, Kim JA, Chlebowski RT. Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence. Breast Cancer Res 2005;7:R535-40 (Epub)
11. IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817-24
12. Sestak I, Cuzick.J. Influence of hormone replacement therapy (HRT) on tamoxifen induced menopausal symptoms (abstract). Ear J Cancer 2005;3 (Suppl 1):9
13. Rotmensz N, Decensi A, Maisonneuve P, et al., on behalf of the Italian Tamoxifen Study Group. Rationale for a study adding tamoxifen to HRT. Eur J Cancer 2002;38 (Suppl 6):S22-3
14. Kroiss R, Fentiman IS, Helmond FA, et al. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. Br J Obstet Gynaecol 2005; 112:228-33
15. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2002;356:2059-63
16. Stearns V, Isaacs C, Rowland J, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000;11:17-22
17. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20: 1578-83
18. Suvanto-Luukkonen E, Koivunen R, Sundstrom H, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomised, 9-month, placebo-controlled, double-blind study. Menopause 2005;12:18-26